Phaseline

Companies › Nanobiotix

Nanobiotix: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NBTXR3
Nanometric crystalline yttrium oxide activated by radiotherapy to generate localized Auger
–Phase 1RadiotherapyApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03589339NBTXR3Phase 1RadiotherapyOncologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.